Jul. 21 at 12:01 PM
$HELP: Could Phase 3 Data Be the Next Major Catalyst? 📈
Helus Pharma is a clinical stage biotech developing next generation treatments for major depressive disorder and other mental health conditions. Its lead candidate, HLP003, remains on track for a Q4 2026 Phase 3 topline data readout.
🔬 Recent Highlights
🔹 Phase 3 enrollment has surpassed 86%, with topline data expected in Q4 2026.
🔹 FDA Breakthrough Therapy Designation supports an accelerated development pathway.
🔹 Completed a
$50M financing, strengthening the balance sheet ahead of key milestones.
🔹 Big Pharma is validating the space. Eli Lilly's up to
$3.8B psychedelic medicine acquisition and Johnson & Johnson's 66% YoY SPRAVATO sales growth to
$438M reinforce the opportunity in next generation depression therapies.
🔹 Prior clinical data showed 100% response and 71% remission rates after two doses of HLP003.
Communicated Disclaimer: https://tinyurl.com/TherealshortsqueezyHELP
Sector Peers:
$ATAI $CMPS $GHRS $NRXP
